Optus Pharmaceutical옵투스제약
131030 · KOSDAQ · ₩131030 · 옵투스제약
₩5,890▼ ₩60 (1.01%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 56.3% | 55.3% | 54.6% | 57.2% | 54.1% | 56.7% |
| Operating margin | 10.7% | 10.2% | 10.5% | 11.3% | 9.0% | 18.3% |
| Net margin | 13.1% | 13.0% | 12.6% | 14.9% | 8.5% | 17.3% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +8.4% | +6.4% | +13.1% | +23.5% | +2.3% | — |
| Operating income growth | +13.9% | +3.3% | +4.9% | +55.7% | −49.8% | — |
| Net income growth | +9.3% | +10.2% | −4.2% | +114.7% | −49.3% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 7.2% | 7.4% | 7.4% | 8.3% | 4.0% | 7.8% |
| Return on assets | 6.4% | 6.4% | 6.5% | 7.5% | 3.6% | 7.1% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 9.8% | 15.8% | 15.8% | 11.2% | 9.5% | 10.2% |
| Net debt to equity | — | — | — | — | — | — |
| Current ratio | 402.5% | 262.3% | 369.0% | 702.0% | 833.8% | 800.1% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Optus Pharmaceutical / 옵투스제약 / 131030 / KRX:131030
Source: KRX statistical information